Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904546 | 0.85 | CA12 (0.46) | MAPTKDM4ECYP3A4LMNACA12 | |
| SCHEMBL1982985 | 0.80 | CYP3A4 (0.47) | MAPTKDM4ECYP3A4LMNANCOA1 | |
| SCHEMBL1416592 | 0.79 | MAPT (0.50) | MAPTKDM4ECYP3A4LMNANCOA1 | |
| SCHEMBL22607244 | 0.79 | KDM4E (0.48) | KDM4ECA12CA9SMN1; SMN2PARP1 | |
| SCHEMBL29611187 | 0.79 | KDM4E (0.48) | KDM4ECA12CA9SMN1; SMN2PARP1 | |
| SCHEMBL28718999 | 0.79 | MAPT (0.50) | MAPTKDM4ECYP3A4LMNANCOA1 | |
| SCHEMBL30538321 | 0.77 | MAPT (0.52) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL7846153 | 0.77 | CYP3A4 (0.47) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL10528166 | 0.77 | HCAR2 (0.41) | MAPTKDM4ELMNACA12CA9 | |
| SCHEMBL29852620 | 0.75 | MAPT (0.54) | MAPTKDM4ECYP3A4LMNANCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004076641-A2 | NEW MICROORGANISM IMPLICATED IN INTESTINAL DISEASES, ALZHEIMER’S DISEASE AND OTHER DISEASES | JJ & C, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-4730014-A | COLORING HIGH-MOLECULAR WEIGHT ORGANIC MATERIALS | CIBA-GEIGY CORPORATION (US) | 1988-03-08 | — | — | US | claimed |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3773602-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-02-17 | — | — | EP | disclosed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | disclosed |
| US-20190328687-A1 | Antibacterial Compounds | VICTORIA LINK LIMITED (NZ) | 2019-10-31 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| EP-3220919-A1 | ANTIBACTERIAL COMPOUNDS | Victoria Link Limited (NZ) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016080846-A1 | ANTIBACTERIAL COMPOUNDS | COPP JANINE NAOMI (NZ) | 2016-05-26 | — | — | WO | disclosed |
| CN-103384724-A | Nmr systems and methods for the detection of analytes | T2 BIOSYSTEMS INC | 2013-11-06 | — | — | CN | disclosed |
| WO-1991012004-A1 | TOPICAL USE OF 6-N-BUTYL-1,4,7,10-TETRAHYDRO-4,10-DIOXO-1,7-PHENANTHROLINE-2,8-DICARBOXYLIC ACID DERIVATIVES | ALLERGAN, INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0265383-A3 | USE OF PYRIDOQUINOLONE DERIVATIVES AS PIGMENTS | CIBA-GEIGY AG (CH) | 1990-08-22 | — | — | EP | disclosed |
| US-4782153-A | HEAT-RESISTANT YELLOW DYES | CIBA-GEIGY CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| US-4782153-A | HEAT-RESISTANT YELLOW DYES | CIBA-GEIGY CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| US-4782153-A | HEAT-RESISTANT YELLOW DYES | CIBA-GEIGY CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0265383-A2 | Use of pyridoquinolone derivatives as pigments | CIBA-GEIGY AG (CH) | 1988-04-27 | — | — | EP | disclosed |
| US-4730014-A | COLORING HIGH-MOLECULAR WEIGHT ORGANIC MATERIALS | CIBA-GEIGY CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
| US-4730014-A | COLORING HIGH-MOLECULAR WEIGHT ORGANIC MATERIALS | CIBA-GEIGY CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
| US-4730014-A | COLORING HIGH-MOLECULAR WEIGHT ORGANIC MATERIALS | CIBA-GEIGY CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | MAPT 4827/4885KDM4E 803/4885CYP3A4 525/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | MAPT 4827/4885KDM4E 803/4885CYP3A4 525/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | MAPT 4714/4885KDM4E 2930/4885CYP3A4 866/4885 |
| US-20190328687-A1 | Antibacterial Compounds | SHARPIN, FDPS, BROX | MAPT 3628/4885KDM4E 2875/4885CYP3A4 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.